Explore our Featured Insights
Ours and others’ latest thinking on the issues that matter most in Advanced Therapy.
Trending Insight
“This landscape mapping provides a detailed understanding of the stakeholders, initiatives, and resources driving this sector's growth in Australia, from small companies, manufacturing facilities and clinical trials, to service and product providers. The report scopes the diversity of therapeutic platforms within Advanced Therapies, identifying Australian strengths and potential opportunities to shape the ecosystem moving forward.”
Client
Melbourne University, Australia
Year
2024
Featured Insights
Select number of insights written and co-authored by HOYA.
Synergy in Cell Therapy Development through Mutual Respect
The model developed by Novo Nordisk, Karolinska Institutet, St Erik, and Vecura was conceptualized and implemented by Dr. Heather Main, Co-founder of HOYA.
hPSC-ATMP manufacture - Where are we now?
Read our first white paper on Manufacturing, the first in a series of white papers we’ve produced after conducting our pilot study with Tillväxtverket.
Author, HOYA co-founder Heather Main.
Australia Cell and Gene Therapy Landscape Mapping
We’re excited to release this detailed landscape mapping report, sponsored by the University of Melbourne. It highlights the key stakeholders, clinical trials, GMP manufacturers, and more in Australia’s growing CGT ecosystem.
An hPSC-ATMP innovation catalyst in Sweden - pilot study
The ATMP Sweden article summarises the hPSC-ATMP Tillväxtverket pilot study and HOYA’s company formation.
Pluripotent stem-cell-derived therapies in clinical trial: A 2025 update
The paper reviews the landscape of interventional hPSC trials worldwide, highlighting available data on clinical safety and efficacy. As of December 2024, the authors identify 115 clinical trials with regulatory approval, testing 83 hPSC products.